Introduction
Under physiological conditions, activation-induced cytidine deaminase (AID) is expressed in germinal center (GC) B-cells and initiates somatic hypermutation (SHM) and class-switch recombination (CSR) by deaminating a cytosine to create a uracil. 1, 2 Structurally, the N-terminal or C-terminal domain of AID is indispensable for SHM or CSR, respectively. [3] [4] [5] Interestingly, expression of AID is increased in B-lymphoid leukemia or GC-derived B-lymphoma, with frequent hypermutation of proto-oncogenes and reciprocal chromosomal translocation. [6] [7] [8] [9] In fact, recent studies have shown that AID is required for GC-derived lymphomagenesis and c-Myc/IgH chromosomal translocations. 10, 11 In addition, elevated expression of endogenous AID and aberrant somatic mutations in tumor-related genes have also been observed in cancerous tissues related to inflammation. 12 Analysis of AID-transgenic (Tg) mice has revealed that constitutive expression of AID leads to tumorigenesis; ubiquitous and constitutive expression of AID induced lethal T-lymphoma with no apparent chromosomal translocation, occasionally accompanied by lung, liver, and gastric cancers, 13, 14 and specific expression of AID in double-positive thymocytes also induced T-lymphoma. 15 However, neither AID-Tg mice specifically expressing AID in single-positive thymocytes and mature T-cells nor AID-Tg mice with CD19 þ B-cell-specific expression of AID developed lymphoma/ leukemia. 15, 16 These results suggest that susceptibility to AIDinduced tumorigenesis depends on tissue or cell lineage, but the underlying mechanism remains obscure. Importantly, sequencing analysis in AID-Tg mice indicated that AID is an organ-specific mutator of non-Ig genes. 14 To prevent accumulation of unfavorable mutations induced by AID, its activity is tightly regulated by several mechanisms. 17 In this study, we focused on AID-mediated leukemogenesis and created a mouse bone marrow transplantation (BMT) model, using BM cells retrovirally transduced with AID. Notably, recipient mice developed B-leukemia/lymphoma, albeit less frequently as compared with thymic T-lymphoma.
Materials and methods

Retroviral constructs, transfection, and retrovirus production
Murine AID (mAID), mAID mutants (G23S 4 and D189-198 5 ), human AID (hAID), and hAID mutants (P20 3 and JP8B 3 ) were subcloned into the pMYsIG vector as described in 'Supplementary Materials and methods'. All constructs were verified by DNA sequencing. Expression of wild-type or mutant AID was recognized in 293T cells transiently transfected with each construct. Retroviruses were generated by transient transfection of Plat-E packaging cells with FuGene 6 (Roche Diagnostics, Mannheim, Germany), as described earlier. [18] [19] [20] 
Mouse BMT
Mouse BMT was performed as described earlier.
20 C57BL/6 CD45.1 or CD45.2 mice were used as donors or recipients, respectively. Infected cells (2 Â 10 5 ) were intravenously injected into recipient mice, which had been administered a sublethal dose of g-irradiation. Overall survival was estimated using the Kaplan-Meier method and log-rank test. Data are presented as the means ± s.d. PB smears and cytospin slides were stained with Hemacolor (Merck, Darmstadt, Germany). Tissues were fixed in 4% w/v buffered formalin, embedded in paraffin, and then sliced and stained with standard hematoxylin and eosin. All animal studies were approved by the Animal Care Committee of the Institute of Medical Science, The University of Tokyo.
Flow cytometric analysis
Cells were stained with phycoerythrin-conjugated monoclonal antibodies (eBiosciences, San Diego, CA, USA), as described. 20 Flow cytometric analysis was performed with a FACSCalibur equipped with CellQuest software (BD Biosciences, San Jose, CA, USA) and Flowjo software (Tree Star, San Carlos, CA, USA).
Western blotting
Equal numbers of cells were denatured in pre-heated sample buffer. Western blotting was performed as described. 20 Anti-AID mAb raised against the N-terminus of mAID, and anti-a-tubulin Ab (T6074, Sigma-Aldrich, St Louis, MO, USA) were used.
Southern blotting
Southern blotting was performed as described. 20 Briefly, 10 mg of genomic DNA digested with EcoRI was electrophoresed on a 0.7% agarose gel. Proviruses were probed with a 32 P-labeled GFP probe.
Reverse transcription and real-time PCR
Real-time PCR was performed using LightCycler (Roche Diagnostics), as described. 20 cDNA was amplified using a SYBR Premix EX Taq (Takara, Shiga, Japan). Primer pairs and conditions used for real-time PCR are listed in 'Supplementary Materials and methods'. Informed consent for the use of the human leukemia/lymphoma cells was obtained from patients in accordance with the Declaration of Helsinki, and study approval was obtained from the ethics committee of the Institute of Medical Science, the University of Tokyo (Approval Number 20-10-0620).
Sequencing of target genes
Genomic PCR was performed by using AmpliTaq Gold (Roche Molecular Systems Inc., Branchburg, NJ, USA) and the primer pairs described in 'Supplementary Materials and methods'. The PCR products were gel-purified and directly sequenced. If necessary, PCR products were subcloned and sequenced.
Treatment of AID-induced T-lymphoma cell lines with g-secretase inhibitor
Cell lines of AID-induced T-lymphoma were established by culturing tumor cells in RPMI1640 with 20% FBS. Human T-acute lymphoblastic leukemia (T-ALL) cell lines Jurkat and HPB-ALL were cultured in RPMI1640 with 10% FBS. Various concentrations of g-secretase inhibitor (DAPT, 565770, Calbiochem, Darmstadt, Germany) or vehicle (DMSO, Wako, Osaka, Japan) were added to 5 Â 10 3 cells for 72 h. Cell growth was estimated by using CellTiter-Glo (Promega, Madison, WI, USA). Cleavage of intracellular domains of Notch1 (ICN) was detected by anti-ICN antibody (2421, Cell Signaling, Beverly, MA, USA) in western blotting.
Results
Transduction with AID into BM cells causes B-leukemia/lymphoma as well as thymic T-lymphoma in a mouse BMT model First, we asked whether transduction of wild-type mAID (WT) into BM cells caused leukemia/lymphoma other than T-lymphoma in a BMT model (n ¼ 32) (Figure 1 ). We confirmed efficient retrovirus infection: 50-70% and 76-84% of the BM cells transduced with WT or mock, respectively, were GFP-positive before transplantation. The recipient mice of WT-transduced cells developed thymic T-lymphoma more frequently than did AID-Tg mice 13 Table 1) . Spleen and BM were filled with B-lymphoblastic cells in most cases, while affected lymph nodes differed in size among cases. B-lymphoma cells were B220 We next asked whether the integration of retroviruses influenced the different phenotypes (T-or B-lymphoma) in AID-induced leukemogenesis. Southern blot analysis demonstrated a single or several proviral integrations in T-lymphoma samples (Figure 1e, left panel) . On the other hand, we found that a single integration was predominant in B-lymphoma samples (Figure 1e , right panel). In one recipient harboring both T-and B-lymphoma, a distinct integration was confirmed in each sample (Figure 1e , right panel, lanes *B and *T), indicating the double cancer in this case. We identified a single or several retroviral integration sites (RIS) from lymphoma samples by inverse PCR method (Supplementary Table 2 ). However, we could not find any specific relationship between RIS and different phenotypes of lymphomas. In addition, a common integration site was identified only in one recipient (ID69) (Supplementary Table 2 ). These results suggested that AID-induced lymphomagenesis mainly depended on its intrinsic function, but not RIS.
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We then asked whether other hematopietic malignancies, including myeloid leukemia, are induced in the absence of thymus. We used athymic nude mice as recipients of a BMT model, finding that 5 of 8 nude mice transplanted with AIDtransduced BM cells developed B-leukemia/lymphoma, but no other hematopoietic diseases were observed (Supplementary Figure 3) . Thus, B-leukemia/lymphoma was predominantly induced in the absence of thymus, but transduction of AID into BM cells did not induce myeloid leukemia. Altogether, these results suggested that the oncogenic transformation of AID-transduced BM cells requires in vivo environment suitable for differentiation and proliferation of immature lymphoid cells.
Impaired lymphomagenesis by SHM-defective AID mutants
To examine how SHM and/or CSR activities of AID contribute to lymphomagenesis, we constructed a BMT model using mutant forms of AID: missense mutant G23S with decreased SHM activity 4 ; and truncation mutant D189-198 defective for CSR AID-induced lymphomagenesis in a BMT model Y Komeno et al activity ( Figure 2a , left panel). 5 Interestingly, recipients of these mutants showed a significantly decreased incidence of lymphoma as compared with those of WT (G23S n ¼ 1/9, 11%; D189-198 n ¼ 1/17, 6%) (Figure 2b, left panel) . Each mutant developed only T-lymphoma. The expression level of G23S was comparable with that of WT in GFP-sorted BM cells (Figure 2c , left panel). On the other hand, the expression of D189-198 mutant in GFP-sorted BM cells was hardly detectable (Figure 2c , left panel). Similar results were obtained when hAID and its C-terminal mutants JP8B and P20 were transduced into BM cells (Figures 2a-c, right panels) . Therefore, it was difficult to evaluate the effect of the CSR activity of AID on lymphomagenesis. Altogether, these results suggest that the intact form of AID with SHM activity is required to maximally exert its oncogenic activity.
An active mutation of K-ras in one case as well as multiple point mutations of Notch1, PTEN, and c-Myc was observed in AID-induced T-lymphoma As point mutations are introduced into non-Ig genes such as TCR or c-Myc gene in T-lymphoma cells of AID-Tg mice, 13 we next asked which mutations caused by AID were responsible for T-lymphomagenesis in a mouse BMT model. On the basis of the fact that AID-mediated mutations occur after about 100 nucleotides downstream of the promoter and extend to 1-2 kb, 24 we performed genomic sequencing of several possible target genes in the region encompassing 0.5-1 kb from the transcription start site, in addition to the mutational hotspots implicated in tumorigenesis (Supplementary Table 3 and data not shown). Similar to the results on AID-Tg mice, 13 multiple mutations were observed in the c-Myc gene. An activating mutation of K-ras (G13D) was detected in 1 out of 14 analyzed samples, although no mutation was found in N-ras, H-ras, or p53 tumor suppressor gene. As for genes involved in human T-ALL, Notch1 25 and Pten, but not Fbxw7, had multiple mutations. Intriguingly, we found several mutations in exon 27 (HD domain) and exon 34 (PEST domain), mutational hotspots of Notch1 far downstream from the transcription start site. Consistent with the earlier report, 13 detected mutations were predominantly transition mutations and strongly biased to GC bases. Collectively, multiple mutations in T-lymphoma were introduced by AID, probably in association with lymphomagenesis.
Most AID-induced T-lymphoma cells exhibited constitutive activation of Notch1 and were susceptible to a g-secretase inhibitor
The finding that Notch1 mutations were observed in AIDinduced T-lymphoma led us to address the question of whether these mutations caused the activation of Notch1, leading to T-lymphomagenesis. Interestingly, western blot analysis demonstrated that cleavage of intracellular Notch1 (ICN) was evident in most T-lymphoma samples tested (Figure 3a) , indicating that constitutive activation of Notch1 occurred in most T-lymphoma cells. In support of this finding, real-time PCR analysis showed increased expression of Hes1 and c-Myc and decreased expression of PTEN in most samples (Figure 3b ). Expression levels of Notch1 did not significantly vary among these samples, except for a few cases. Interestingly, when we treated two cell AID-induced lymphomagenesis in a BMT model Y Komeno et al lines established from AID-induced T-lymphoma with a g-secretase inhibitor, DAPT, the growth as well as the cleavage of ICN of these cell lines was dose dependently inhibited by DAPT (Figures 3c and d) . Although Notch1 mutations did not account for constitutive activation of Notch1 in all cases, these results indicated that T-lymphomagenesis in most cases was induced by Notch1 activation, probably in conjunction with AID-introduced mutations of the related genes.
Truncation mutations of Ebf1 and Pax5 were found in AID-induced B-lymphoma
To investigate the relevant mechanism of AID-induced B-lymphomagenesis, we performed genomic sequencing of the Ebf1 and Pax5 genes of AID-induced B-leukemia/lymphoma of seven recipient mice (Supplementary Table 4 and data not shown). Intriguingly, sequencing of Ebf1 revealed a 23-base deletion and a 4-base insertion in exon 2, which together resulted in truncation in one sample. In addition, multiple point mutations were found in three samples. As for Pax5, we found a truncation caused by a couple of 2-base deletions and a point mutation in exon 1a in one case, and point mutations in two cases. On the basis of the recent study, 26 the aberrations of Pax5 and Ebf1 genes described above might have some function in B-lymphomagenesis in the recipient mice. On the other hand, we did not find c-Myc/IgH chromosomal translocations in B-lymphoma samples analyzed by PCR combined with Southern blotting (data not shown). 27 Collectively, these results suggested that B-lymphomagenesis in a BMT model was, at least in part, due to AID-introduced mutations/deletions of the genes regulating B-cell differentiation.
Discussion
In this study, we constructed a mouse BMT model to test whether AID is implicated in the pathogenesis of leukemia/ lymphoma including myeloid leukemia. Our results revealed that aberrant expression of AID in BM cells led to T-lymphoma and less frequently B-leukemia/lymphoma, but not myeloid leukemia (Figure 1 ). The recipient mice developed 'thymic' T-lymphoma, but not 'peripheral type' T-lymphoma observed in 65% of AID-Tg mice. 13 It was noteworthy that B-leukemia/ lymphoma was observed in our BMT model, but not in AID-Tg 
AID-induced lymphomagenesis in a BMT model
Y Komeno et al mice, 13, 15, 28 because AID is implicated in the pathogenesis of human B-cell malignancy. [6] [7] [8] [9] Interestingly, nude mice developed only B-leukemia when used as recipients, probably due to lack of thymus (Supplementary Figure 3) . The differences between AID-Tg mice and the BMT model were probably caused by the expression levels in the different types of cells, although we could not completely exclude the possibility that RIS affected the phenotypes. We have two hypotheses for AID-induced lymphomagenesis in the BMT model: (1) AIDtransduced stem/progenitor cells may move to thymus, where they would be susceptible to AID-mediated mutations and rapidly acquire oncogenic properties at an early stage of T-lineage development; (2) AID could introduce some mutations and transform cells at stem/progenitor levels, which would commit to T-lineage in thymus. Otherwise, AID-transduced stem/progenitor cells would be transformed during the early B-lineage development in BM and spleen, which result in B-leukemia/lymphoma. Both hypotheses would explain why no lymphoma was observed in AID-Tg mice with its expression restricted to mature lymphocytes. 15, 28 However, it is not clear why AID overexpression did not induce myeloid leukemia. We found scarcely detectable levels of AID in human myeloid malignancy (Supplementary Figure 4) . Recent study showed that chronic myeloid leukemia (CML) does not express AID unless CML cells are forced into B-lineage conversion by Pax5. 9 It is possible that the protective machinery efficiently works against AID functioning as a mutator in myeloid cells, but not in lymphoid cells. Indeed, we confirmed that AID overexpression did not affect myeloid cell development in BM one month after transplantation (data not shown). In addition, sorted myeloid progenitors (common myeloid progenitors and granulocytemacrophage progenitors) transduced with AID did not cause myeloid leukemia in our BMT model (data not shown). According to the recent studies, the balance between errorprone repair (EPR) and high-fidelity repair (HFR) determines the outcome of AID-generated uracils, that is, accumulation or elimination of mutations. 29 It is tempting to speculate that the frequencies of uracils generated by AID are not different between the myeloid-and lymphoid-lineage, but that HFR overcomes EPR in the myeloid-lineage. In any case, solving the riddle of how AID induces leukemia/lymphoma in a celllineage-dependent manner will help understand AID functions.
It is generally accepted that the N-terminal or C-terminal domain of AID is important for SHM or CSR activity, respectively, [3] [4] [5] but neither activity is regulated in an exclusively distinct way. Our results showed that AID mutants with decreased SHM or CSR activity have impaired oncogenic activity ( Figure 2 ). It must be noted that expression levels of mouse mutant D189-198 as well as human mutants JP8B and P20 in GFP-sorted BM cells were lower than those of WTs, possibly due to protein instability of these C-terminal mutants. 30 Therefore, we cannot answer the question whether CSR activity is indispensable for oncogenicity of AID, but we assume that the maximum ability of AID to cause lymphoma requires an intact form of AID with SHM activity.
We clarified to some extent the mechanism by which AIDintroduced mutations of tumor-related genes led to lymphomagenesis (Supplementary Table 3 ). As reported on AID-Tg mice, 13 multiple mutations of the c-Myc gene were found in T-lymphoma samples. The Notch1 gene was mutated in exon 1 and mutational hotspots (HD and PEST domains) in four cases. Intriguingly, Notch1 was constitutively activated in T-lymphoma more frequently than expected from the mutation frequency of Notch1 (Figure 3) . We speculate that AID-mediated mutations of other genes caused secondary Notch1 activation, resulting in T-lymphoma. However, one such candidate, Fbxw7, 31 did not have significant mutations. Further examination will identify unknown mutations responsible for human T-lymphoma/ leukemia.
Sequencing analysis of AID-induced B-leukemia/lymphoma samples revealed frequent mutations in the Ebf1 and Pax5 genes (Supplementary Table 4 and data not shown). Importantly, we found truncation mutations in Ebf1 and Pax5 that probably have oncogenic properties; mono-allelic deletions of these genes were observed in human B-ALL. 26 As for chromosomal instability, c-Myc/IgH translocation was not detected (data not shown). The presence of TCR translocations was unlikely, as no chromosomal translocation was detected in AID-induced T-lymphoma observed in AID-Tg mice. 13, 15 The present results suggest that, like thymic T-lymphoma, B-leukemia/lymphoma was induced by AID-introduced mutations/deletions of the key molecules regulating B-cell differentiation and/or proliferation.
In conclusion, this is the first report on the potential of AID overexpression to promote B-cell lymphomagenesis. Aberrant expression of AID in bone marrow cells induced leukemia/ lymphoma in a cell-lineage-dependent manner, probably because an intact form of AID efficiently introduced mutations into the responsible genes, thereby disrupting normal development of lymphoid progenitors.
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